Table 1.
Patient characteristics.
| UC | Control | |
|---|---|---|
| Total | 104 | 39 |
| Age (years), (mean ± SD) | 12.6 ± 2.6 | 10.8 ± 2.9 |
| Males, n (%) | 51 (49%) | 18(46%) |
| Disease extent | ||
| E1 (proctitis) | 7 | |
| E2 (left-sided) | 17 | |
| E3 (extensive) | 5 | |
| E4 (pancolitis) | 75 | |
| Medications | ||
| Aminosalicylate | 71 | |
| Corticosteroids | 17 | |
| Azathioprine/6-MP | 32 | |
| Biologic drugs | 16 | |
| Tacrolimus | 1 | |
| No medication | 21 | |
| PGE-MUM by CLEIA (μg g−1 Cr−1), median (IQR) | 23.1 (16.1–38.6) | |
| All* | 28.5 (16.2–46.3) | 18.6 (15.7–22.6) |
| Male* | 31.3 (17.0–47.9) | 18.7(14.8–24.1) |
| Female* | 26.0 (16.2–42.1) | 18.6 (17–21.5) |
| PGE-MUM by RIA (μg g−1 Cr−1), median (IQR) | 21.7 (14.9–34.9) | |
| FCP, median (IQR) | 2480 (300–4830) | |
| CRP (mg/dl), median (IQR) | 0.04 (0.02–0.12) | |
| ESR (mm), median (IQR) | 11 (5–19) | |
| Clinical activity, PUCAI | ||
| median (IQR) | 20 (0–45) | |
| < 10/10–34/35–64/65 < | 41/28/28/7 | |
| Endoscopic activity, MES† (104 subjects) | ||
| Median (IQR) | 2 (1–3) | |
| 0/1/2/3, n | 10/29/37/28 | |
| Histologic activity, Matts‡ (76 subjects) | ||
| Median (IQR) | 4 (4–5) | |
| 1/2/3/4/5, n | 6/3/8/22/37 | |
| Intervals of urine sampling and colonoscopy, day, mean (SD) | 1.2 ± 2.0 | |
| Intervals of fecal sampling and colonoscopy, day, mean (SD) | 1.6 ± 3.2 | |
CRP C-reactive protein, ESR erythrocyte sedimentation rate, IQR interquartile range, 6-MP 6-mercaptopurine, MES Mayo endoscopic score, PGE-MUM Prostaglandin E-major urinary metabolite, PUCAI Pediatric Ulcerative Colitis Activity Index, UC ulcerative colitis; *P < 0.001 †Maximum MES among 6 segments (the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, and rectum). ‡Maximum Matts among 6 segments.